Would the recent use of high dose glucocorticoids impact your selection of first-line therapy for patients with intermediate-poor risk metastatic RCC?
For example, in a patient on steroids for CNS or spinal metastases - would you use IO-IO vs IO-TKI or TKI monotherapy?